海思科(002653.SZ)：创新药环泊酚注射液获得拓展儿童人群批准

Core Viewpoint - Company Haisco (002653.SZ) has received approval from the National Medical Products Administration for its new drug, Ropivacaine Injection, which is a novel intravenous anesthetic with independent intellectual property rights [1] Group 1: Product Development - The product, Ropivacaine Injection (also known as "Sishuning®"), is classified as a Class 1 intravenous anesthetic [1] - It was approved for domestic market launch in December 2020 [1] - The drug has obtained registration certificates for multiple indications, including sedation and anesthesia during non-tracheal intubation surgeries, induction and maintenance of general anesthesia, and sedation during intensive care [1]